Identify equivocal lesions where an objective risk assessment would be helpful.
Use our device to analyse, and receive an "Investigate Further" or "Monitor" result.
Counsel your patient on next steps using the objective result to assist in your decision making.
- Simple design, effortless application
- Non-invasive optical spectroscopy
- Beneath the skin, cellular-level analysis
- AI-Powered, ultra-minitiarized ESS Technology
- 68% decrease in missed skin cancers with use of the device1
- 96% sensitivity across common skin cancers2
DermaSensor’s technology holds the promise of improving early detection of skin cancer by equipping primary care providers with a tool to better assess it.
David Leffell, M.D.
Chief, Section of Dermatologic Surgery and Cutaneous Oncology, Yale School of Medicine Scientific Advisory Board, DermaSensor
DermaSensor looks beyond the visual to improve your decision-making and confidence.
According to the results of a study with 57 GPs, skin cancer detection increases by 13% (from 81% to 94% sensitivity) when using DermaSensor, with no significant decrease in specificity.1
1Tepedino K, Tablada A, Barnes E, Da Silva, T. Clinical Utility of a Handheld Elastic Scattering Spectroscopy Tool and Machine Learning on the Diagnosis and Management of Skin Cancer by Primary Care Physicians. Poster Presentation, SDPA Fall Conference, Nov 4-7, 2021.
2DA III- Hartman, R. Tepedino, K., Fung, MA., McNiff, JM., Grant-Kels, J. Clinical Validation of a Handheld Elastic Scattering Spectroscopic Device in the Evaluation of Lesions Suggestive of Melanoma, Presentation at the American Academy of Dermatologists Annual Meeting, Mar 24-28th, 2022.
DermaSensor demonstrated 93% sensitivity across melanoma, BCC and SCC (95% for melanoma). DermaSensor use was found to increase physicians’ cancer detection sensitivity from 81% to 94%, and this improvement was statistically significant (p = .0009). There was no statistically significant change in the GP’s specificity, or false positive rate, for benign lesions (p = .3558).